AbbVie Inc. (NYSE:ABBV) ranks among the best retirement stocks to buy now.
Piper Sandler increased its price target for AbbVie Inc. (NYSE:ABBV) to $298 from $294 on May 14, retaining an Overweight rating on the company’s shares
The firm mentioned AbbVie’s extensive inflammatory bowel disease pipeline as a major source of investor interest. Pixabay/Public Domain AbbVie Inc. (NYSE:ABBV) submitted 18 abstracts on inflammatory bowel illnesses at the 2026 Digestive Disease Week Annual Meeting, which was held in Chicago from May 2 to 5. The research centered around real-world evidence and long-term results for the company’s Crohn’s disease and ulcerative colitis therapies, SKYRIZI and RINVOQ.
The presentation featured 52-week follow-up results from the ASPIRE-CD study, which demonstrated that risankizumab-treated individuals with moderately to highly active Crohn’s disease had long-lasting improvements in liquid stools, bowel urgency, and abdominal pain. Piper Sandler stated that management’s pursuit of novel combination methods in IBD is a positive development, considering the competitiveness of the IBD medication development landscape. According to the firm, one factor that makes AbbVie Inc. (NYSE:ABBV) appealing is the variety of R&D shots-on-goal that stay beneath the radar of the general investment market.